Cite

HARVARD Citation

    Genovese, M. et al. (2018). Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology. pp. 2001-2011. [Online]. 
  
Back to record